Savara Inc (SVRA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Savara Inc (SVRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9832
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of treatment of PAP; and AeroVanc, an inhaled formulation of vancomycin for the treatment of CF. Its development pipeline also includes Aironite, a sodium nitrite solution for intermittent inhalation for the treatment of heart failure. The company has subsidiaries in the US and Denmark. Savara is headquartered in Austin, Texas, the US.

Savara Inc (SVRA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Savara Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Savara Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Savara Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Savara Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Savara Inc, Medical Devices Deals, 2012 to YTD 2018 10
Savara Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Savara Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Savara Acquires Certain Assets and Rights from Cardeas Pharma 13
Venture Financing 14
Savara Pharma Raises USD20 Million in Series C Financing Round 14
Savara Pharmaceuticals Secures USD18.54 Million in Venture Funding 15
Savara Pharma Raises Additional USD5.5 Million in Financing Round 16
Savara Pharma Raises USD4.5 Million in Financing Round 17
Savara Pharma Raises US$14 Million In Series B Financing 18
Partnerships 19
Aires Pharma Enters into Agreement with University of Pittsburgh 19
Serendex Pharma Enters into Agreement with CMC Biologics For Factor VII 20
Merger 21
Mast Therapeutics Merges with Savara 21
Licensing Agreements 23
NobelPharma Enters into Licensing Agreement with Savara 23
NobelPharma Enters into Licensing Agreement with Serendex Pharma 24
Equity Offering 25
Savara Prices Public Offering of Shares for USD48.9 Million 25
Savara Prices Public Offering of Shares for USD47.3 Million 26
Savara Raises USD42.9 Million in Public Offering of Shares 28
Savara to Raise up to USD18 Million in Public Offering of Shares 29
Savara Raises USD8 Million in Public Offering of Shares and Warrants 30
Serendex Pharma Raises USD12.7 Million Rights Offering of Shares 31
Savara Raises USD21 Million in Public Offering of Shares and Warrants 33
Savara Raises USD0.9 Million in Public Offering of Shares up on Exercise of Warrants 34
Serendex Pharma Completes IPO for USD11 Million 35
Savara Raises USD30 Million in Public Offering of Shares 37
Acquisition 38
Savara Pharma Acquires Serendex Pharma 38
Mast Therapeutics Completes Acquisition Of Aires Pharma 39
Savara Inc – Key Competitors 40
Savara Inc – Key Employees 41
Savara Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
May 09, 2018: Savara Reports First Quarter 2018 Financial Results and Provides Business Update 43
Mar 14, 2018: Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 45
Nov 08, 2017: Savara Reports Third Quarter 2017 Financial Results and Provides Business Update 47
Aug 09, 2017: Savara Reports Second Quarter 2017 Financial Results and Provides Business Update 48
Product News 49
03/06/2017: Mast Therapeutics Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients 49
Clinical Trials 50
May 10, 2017: Savara Announces Expedited U.S. Molgradex Development Strategy 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Savara Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Savara Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Savara Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Savara Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Savara Inc, Medical Devices Deals, 2012 to YTD 2018 10
Savara Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Savara Acquires Certain Assets and Rights from Cardeas Pharma 13
Savara Pharma Raises USD20 Million in Series C Financing Round 14
Savara Pharmaceuticals Secures USD18.54 Million in Venture Funding 15
Savara Pharma Raises Additional USD5.5 Million in Financing Round 16
Savara Pharma Raises USD4.5 Million in Financing Round 17
Savara Pharma Raises US$14 Million In Series B Financing 18
Aires Pharma Enters into Agreement with University of Pittsburgh 19
Serendex Pharma Enters into Agreement with CMC Biologics For Factor VII 20
Mast Therapeutics Merges with Savara 21
NobelPharma Enters into Licensing Agreement with Savara 23
NobelPharma Enters into Licensing Agreement with Serendex Pharma 24
Savara Prices Public Offering of Shares for USD48.9 Million 25
Savara Prices Public Offering of Shares for USD47.3 Million 26
Savara Raises USD42.9 Million in Public Offering of Shares 28
Savara to Raise up to USD18 Million in Public Offering of Shares 29
Savara Raises USD8 Million in Public Offering of Shares and Warrants 30
Serendex Pharma Raises USD12.7 Million Rights Offering of Shares 31
Savara Raises USD21 Million in Public Offering of Shares and Warrants 33
Savara Raises USD0.9 Million in Public Offering of Shares up on Exercise of Warrants 34
Serendex Pharma Completes IPO for USD11 Million 35
Savara Raises USD30 Million in Public Offering of Shares 37
Savara Pharma Acquires Serendex Pharma 38
Mast Therapeutics Completes Acquisition Of Aires Pharma 39
Savara Inc, Key Competitors 40
Savara Inc, Key Employees 41
Savara Inc, Subsidiaries 42

List of Figures
Savara Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Savara Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Savara Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Savara Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Savara Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Savara Inc (SVRA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AGR Holdings AS:企業の戦略的SWOT分析
    AGR Holdings AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Taiwan Semiconductor Manufacturing Company Limited
    Taiwan Semiconductor Manufacturing Company Limited - Strategy, SWOT and Corporate Finance Report Summary Taiwan Semiconductor Manufacturing Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • Zygo Corporation:企業の戦略的SWOT分析
    Zygo Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Medigard Ltd (MGZ):医療機器:M&Aディール及び事業提携情報
    Summary Medigard Ltd (Medigard), formerly Medisafe Instruments Pty Ltd, is a medical device company that designs and develops retractable safety medical devices. The company provides products such as auto-retractable syringe, manual retractable syringe, blood collection device, intravenous valve and …
  • Continental Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Continental Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Continental Resources Inc (Continental Resources) is an oil and gas company involved in the distribution of fuel and related products and services. The company offerings include supply fulf …
  • Russian Reinsurance Company:企業の戦略・SWOT・財務分析
    Russian Reinsurance Company - Strategy, SWOT and Corporate Finance Report Summary Russian Reinsurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TrialBee AB:製薬・医療:M&Aディール及び事業提携情報
    Summary TrialBee AB (TrialBee) is a provider of innovative software solutions that accelerates clinical trials. The company provides services such as online patient recruitment, online study feasibility, study retention and electronic data capture, among others. It offers cloud based solution which …
  • Anworth Mortgage Asset Corp (ANH):企業の財務・戦略的SWOT分析
    Summary Anworth Mortgage Asset Corp (Anworth) is a financial service provider that provides mortgage real estate investment services. The company invests in mortgage-backed securities on a leveraged basis. It operates through agency credit-backed securities and non-agency credit-backed securities. A …
  • SATT Conectus Alsace SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary SATT Conectus Alsace SAS (Conectus Alsace), a subsidiary of SATT Association, is a technology transfer service provider. The company offers services such as single entry point, well-defined research collaborations, technology transfers, accessible technology platforms, license approach, inde …
  • Navidea Biopharmaceuticals Inc (NAVB):医療機器:M&Aディール及び事業提携情報
    Summary Navidea Biopharmaceuticals Inc (Navidea) is a biopharmaceutical company that develops precision immunodiagnostic agents and immunotherapeutics.. The company is focused on developing multiple precision-targeted products based on its Manocept platform to improve patient care. Its pipeline prod …
  • Aptevo Therapeutics Inc (APVO):企業の財務・戦略的SWOT分析
    Aptevo Therapeutics Inc (APVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Melkior Resources Inc. (MKR):企業の財務・戦略的SWOT分析
    Melkior Resources Inc. (MKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • OriGene Technologies Inc-製薬・医療分野:企業M&A・提携分析
    Summary OriGene Technologies Inc (OriGene) is a research tool company that develops cDNA. The company creates commercial collection of full-length human cDNAs in expression vector. It develops, manufactures and sells genome research and diagnostic products. OriGene’s products include qPCR reagents, …
  • Denizbank A.S.:企業の戦略・SWOT・財務分析
    Denizbank A.S. - Strategy, SWOT and Corporate Finance Report Summary Denizbank A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • DiaGenic ASA (NEL)-製薬・医療分野:企業M&A・提携分析
    Summary DiaGenic ASA (DiaGenic) is a medical device company that develops innovative in vitro diagnostic products for early detection of diseases. The company specializes in developing blood-based biomarkers. Its ADtect product is a blood test that helps distinguish mild to moderate range AD from th …
  • PostNL NV (PNL):企業の財務・戦略的SWOT分析
    PostNL NV (PNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Abu Dhabi Commercial Bank P.J.S.C.:戦略・SWOT・企業財務分析
    Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Specsavers Optical Group Ltd:企業の戦略・SWOT・財務分析
    Specsavers Optical Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Specsavers Optical Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • The Tokyo Electric Power Company, Incorporated:企業の戦略・SWOT・財務情報
    The Tokyo Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Tokyo Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Marksans Pharma Ltd (MARKSANS):企業の財務・戦略的SWOT分析
    Summary Marksans Pharma Ltd (Marksans Pharma) is a pharmaceutical company that develops, manufactures and markets branded formulations and generic products. The company manufactures non-sterile liquids, ointments and powder products. It offers solid oral dosage in form of tablets, hard gelatin capsu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆